CARBIDOPA; LEVODOPA by Novartis is 12. Approved for parkinson’s disease, post-encephalitic parkinsonism, symptomatic parkinsonism and 1 more indications.
Drug data last refreshed 1h ago
12.1 Mechanism of Action Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral…
Worked on CARBIDOPA; LEVODOPA at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.